Clinical-stage gene therapy company developing treatments for ocular diseases that cause vision loss and blindness
Clinical-stage gene therapy company developing treatments for ocular diseases that cause vision loss and blindness. Its lead program, GT005, is an AAV2-based one-time gene therapy delivering complement regulatory protein CFI for geographic atrophy secondary to age-related macular degeneration. The company is also advancing gene therapies for retinal diseases using its proprietary Orbit subretinal delivery system.